New vessel formation (angiogenesis) is an essential physiological process for embryologic
development, normal growth, and tissue repair. Angiogenesis is tightly regulated at the …

No validated biological markers (or biomarkers) currently exist for appropriately selecting
patients with cancer for antiangiogenic therapy. Nor are there biomarkers identifying escape …

Purpose A phase III trial of bevacizumab combined with interferon alfa-2a (IFN) showed
significant improvements in progression-free survival (PFS) in metastatic renal cell …

Purpose Bevacizumab is an antibody that binds vascular endothelial growth factor and has
activity in metastatic renal cell carcinoma (RCC). Interferon alfa (IFN-α) is the historic …

Background Hypertension (HTN) is an on-target effect of the vascular endothelial growth
factor pathway inhibitor, sunitinib. We evaluated the association of sunitinib-induced HTN …

Abstract Purpose: Axitinib (AG-013736) is a potent and selective inhibitor of vascular
endothelial growth factor (VEGF) receptor tyrosine kinases 1 to 3 that is in clinical …

The development and use of antiangiogenesis agents, particularly those targeting vascular
endothelial growth factor (VEGF), has become an integral component of anticancer …

Context: The treatment of colorectal cancer has improved considerably in recent years, but it
remains the second commonest cause of cancer deaths in men and women in the United …

Vascular endothelial growth factor (VEGF) has been confirmed as an important therapeutic
target in randomised clinical trials in multiple disease settings. However, the extent to which …

BACKGROUND: Sunitinib and sorafenib are tyrosine kinase inhibitors that have important
antitumor activity in metastatic renal cell carcinoma (mRCC). Hypothyroidism constitutes a …